
Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. (SYRE) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · SYRE · as of Jun 8, 2026
Key Statistics
Explore Spyre Therapeutics, Inc. Data
syre stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 11 · Buy rate: 100.0%
The SYRE analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month price target is $86.64, representing +20.40% upside from the current price of $71.96.
Competitors & Peers
syre competitorsStock Performance
Full HistoryAbout Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclona…
what is spyre therapeutics, inc. · syre stock overview · spyre therapeutics, inc. company profile · who is spyre therapeutics, inc. ceo · syre NASDAQ · spyre therapeutics, inc. headquarters · spyre therapeutics, inc. business segments
About Stock Overview & Key Data
Spyre Therapeutics, Inc. (SYRE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Apr 7, 2016. As of the latest trading session, SYRE stock price is $71.96, with a market capitalization of $4.3B. The stock has returned +316.90% over the past 12 months and +118.38% year-to-date.
According to 11 Wall Street analysts, the consensus rating for Spyre Therapeutics, Inc. stock is Buy, with an average 12-month price target of $86.64. In fiscal year 2025, Spyre Therapeutics, Inc. reported revenue of — and net income of -$155.2M. For detailed data — including Spyre Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Spyre Therapeutics, Inc. (SYRE) stock price is $71.96. The stock is traded on NASDAQ under the ticker symbol SYRE. The 52-week range is $13.93 – $78.80.